Tag

daraxonrasib fda approval — 1 page

Closed FDA Approves Daraxonrasib (Rasonque) — First RAS-Targeted Therapy for Metastatic Pancreatic Cancer On Aug 26, 2026 the FDA approved Rasonque (daraxonrasib), Revolution Medicines' first-in-class RAS inhibitor for metastatic pancreatic cancer; trial survival was 13.2 vs 6.7 months. Science · Aug 27